Molecular Neurodegeneration Advances
@molneurodegenadvnc.bsky.social
MN Advances is an open-access, peer-reviewed journal dedicated to advancing research on neurodegen at the molecular, cellular and systems levels. Sister journal to Molecular Neurodegeneration @molneurodegen.bsky.social https://mnadvances.biomedcentral.com/
Early-Onset Alzheimer’s with Loss of Presenilin-1? | ALZFORUM
www.alzforum.org
November 14, 2025 at 6:46 PM
'The curious case of a heterozygous loss-of-function #PSEN1 variant associated with early-onset #AlzheimersDisease'
Inmaculada Sanjuan-Ruiz, Lutgarde Serneels, Katleen Craessaerts...Bart De Strooper @leuvenbrainins.bsky.social @ukdri.ac.uk @viblifesciences.bsky.social
bit.ly/3L0QhK6
Inmaculada Sanjuan-Ruiz, Lutgarde Serneels, Katleen Craessaerts...Bart De Strooper @leuvenbrainins.bsky.social @ukdri.ac.uk @viblifesciences.bsky.social
bit.ly/3L0QhK6
The curious case of a heterozygous loss-of-function PSEN1 variant associated with early-onset Alzheimer’s disease - Molecular Neurodegeneration Advances
Background Over 300 mutations in PSEN1 have been identified as causes of early-onset Alzheimer’s disease (EOAD). While these include missense mutations and a few insertions, deletions, or duplications...
mnadvances.biomedcentral.com
October 22, 2025 at 9:04 PM
'The curious case of a heterozygous loss-of-function #PSEN1 variant associated with early-onset #AlzheimersDisease'
Inmaculada Sanjuan-Ruiz, Lutgarde Serneels, Katleen Craessaerts...Bart De Strooper @leuvenbrainins.bsky.social @ukdri.ac.uk @viblifesciences.bsky.social
bit.ly/3L0QhK6
Inmaculada Sanjuan-Ruiz, Lutgarde Serneels, Katleen Craessaerts...Bart De Strooper @leuvenbrainins.bsky.social @ukdri.ac.uk @viblifesciences.bsky.social
bit.ly/3L0QhK6
Dose-ranging and further therapeutic evaluation of a bicistronic humanized TrkB-BDNF #genetherapy for #glaucoma in rodents
Andrew Osborne, Tasneem Z. Khatib, Michael Whitehead...Keith R. Martin @cambridge.org
mnadvances.biomedcentral.com/articles/10....
Andrew Osborne, Tasneem Z. Khatib, Michael Whitehead...Keith R. Martin @cambridge.org
mnadvances.biomedcentral.com/articles/10....
Dose-ranging and further therapeutic evaluation of a bicistronic humanized TrkB-BDNF gene therapy for glaucoma in rodents - Molecular Neurodegeneration Advances
Background Glaucoma is a leading cause of irreversible blindness, characterized by the progressive degeneration of retinal ganglion cells (RGCs). Activation of the Tropomyosin receptor kinase B (TrkB)...
mnadvances.biomedcentral.com
August 27, 2025 at 2:15 PM
Dose-ranging and further therapeutic evaluation of a bicistronic humanized TrkB-BDNF #genetherapy for #glaucoma in rodents
Andrew Osborne, Tasneem Z. Khatib, Michael Whitehead...Keith R. Martin @cambridge.org
mnadvances.biomedcentral.com/articles/10....
Andrew Osborne, Tasneem Z. Khatib, Michael Whitehead...Keith R. Martin @cambridge.org
mnadvances.biomedcentral.com/articles/10....
Uncovering plaque- #glia niches in human #AlzheimersDisease brains using spatial #transcriptomics
Denis R. Avey, Bernard Ng, Ricardo A. Vialle...Yanling Wang @rushalzheimers.bsky.social #glia
mnadvances.biomedcentral.com/articles/10....
Denis R. Avey, Bernard Ng, Ricardo A. Vialle...Yanling Wang @rushalzheimers.bsky.social #glia
mnadvances.biomedcentral.com/articles/10....
July 24, 2025 at 10:28 PM
Uncovering plaque- #glia niches in human #AlzheimersDisease brains using spatial #transcriptomics
Denis R. Avey, Bernard Ng, Ricardo A. Vialle...Yanling Wang @rushalzheimers.bsky.social #glia
mnadvances.biomedcentral.com/articles/10....
Denis R. Avey, Bernard Ng, Ricardo A. Vialle...Yanling Wang @rushalzheimers.bsky.social #glia
mnadvances.biomedcentral.com/articles/10....
"A new dawn in neurodegeneration research: MN advances"
Our Editor-in-Chief, Dr. Guojun Bu, introduces MN Advances in this inaugural piece — marking the launch of our very first MN Advances publication! Check it out here: bit.ly/4cJ2pZN
Our Editor-in-Chief, Dr. Guojun Bu, introduces MN Advances in this inaugural piece — marking the launch of our very first MN Advances publication! Check it out here: bit.ly/4cJ2pZN
A new dawn in neurodegeneration research: MN advances - Molecular Neurodegeneration Advances
bit.ly
April 22, 2025 at 6:38 PM
"A new dawn in neurodegeneration research: MN advances"
Our Editor-in-Chief, Dr. Guojun Bu, introduces MN Advances in this inaugural piece — marking the launch of our very first MN Advances publication! Check it out here: bit.ly/4cJ2pZN
Our Editor-in-Chief, Dr. Guojun Bu, introduces MN Advances in this inaugural piece — marking the launch of our very first MN Advances publication! Check it out here: bit.ly/4cJ2pZN
👋✨ Introducing Molecular Neurodegeneration Advances!
Building on the success of Molecular Neurodegeneration, MN Advances is an open-access peer-reviewed journal aiming to encompass a wider range of neurodegen diseases while maintaining our commitment to scientific excellence & rigorous peer review
Building on the success of Molecular Neurodegeneration, MN Advances is an open-access peer-reviewed journal aiming to encompass a wider range of neurodegen diseases while maintaining our commitment to scientific excellence & rigorous peer review
April 22, 2025 at 6:37 PM
👋✨ Introducing Molecular Neurodegeneration Advances!
Building on the success of Molecular Neurodegeneration, MN Advances is an open-access peer-reviewed journal aiming to encompass a wider range of neurodegen diseases while maintaining our commitment to scientific excellence & rigorous peer review
Building on the success of Molecular Neurodegeneration, MN Advances is an open-access peer-reviewed journal aiming to encompass a wider range of neurodegen diseases while maintaining our commitment to scientific excellence & rigorous peer review